Publication | Closed Access

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

Metabolic SyndromeDiabetes ManagementHeart FailureHealth PolicyCardiovascular DiseaseDiabetesType 2RiskRetrospective AnalysisCongestive Heart FailureDiabetes MellitusPublic HealthMedicineEpidemiology